Radius Health
950 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-551-4000
Fax: 617-551-4701
Website: http://www.radiuspharm.com/
Email: info@radiuspharm.com
About Radius Health
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
YEAR FOUNDED:
October 3, 2003
LEADERSHIP:
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
JOBS:
Please click here for Radius Health job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
235 articles about Radius Health
-
Radius Announces Royalty Purchase Agreement With DRI Healthcare to Sell a Portion of Its Royalty and Commercial Milestone Interest in elacestrant for up to $140 Million
8/14/2023
Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc., announced that it has entered into a Royalty Purchase Agreement for a portion of Radius’s royalty and commercial milestone stream in elacestrant, the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer, with DRI Healthcare Acquisitions LP.
-
Radius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
12/20/2022
Radius Health, Inc. ("Radius" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved TYMLOS® (abaloparatide), a parathyroid hormone related peptide [PTHrP(1‑34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.
-
Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies.
-
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
7/7/2022
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011,
-
With the submission of NDAs and BLAs, multiple companies are bidding for regulatory approval of drug candidates. BioSpace takes a look at several of the latest requests.
-
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
6/22/2022
The Menarini Group and Radius Health, Inc. announced that Menarini, with support from Radius, has submitted a New Drug Application to the U.S. Food and Drug Administration for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.
-
Radius Health Update on Abaloparatide Transdermal System
6/1/2022
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the abaloparatide transdermal system (abalo-TDS) development program.
-
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
-
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
5/19/2022
The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs. standard of care (SOC; fulvestrant or aromatase inhibitor, AI) for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.
-
Radius Health, Inc. First Quarter 2022 Results
5/5/2022
Radius Health, Inc., reported its financial results for the first quarter ended March 31, 2022.
-
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
4/25/2022
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.
-
Radius Health Announces Leadership Appointments
3/16/2022
Radius Health, Inc., announced appointments to new roles on its executive leadership team, effective immediately.
-
Radius Health Provides Business Update on Bone Health
3/8/2022
On December 15, 2020, Radius announced a discovery research collaboration with Massachusetts General Hospital to evaluate novel oral salt-inducible kinase inhibitors in an array of musculoskeletal diseases.
-
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis
3/1/2022
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update.
-
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
2/24/2022
Radius Health, Inc., reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided key business and financial objectives for 2022.
-
Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022
2/15/2022
Radius Health, Inc. announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022.
-
Radius Announces Update on TYMLOS® (abaloparatide) Label
12/23/2021
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label.
-
Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
12/8/2021
Radius Health, Inc. announced it will host a conference call , Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below.
-
Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis
12/8/2021
Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis.
-
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
12/8/2021
The Menarini Group and Radius Health presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.